COMMUNIQUÉS West-GlobeNewswire

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
30/04/2026
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a company developing advanced artificial intelligence solutions for [...]
SweetWater Brewing Company and Salt Life Launch Livin’ Salty: The Ultimate Summer Craft Brew Collaboration
30/04/2026
Introducing Livin’ Salty: Your Go-To Lager for Sun, Sand, and Summer Fun ATLANTA, April 30, 2026 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the leading craft beer brand in the [...]
Verano Announces Strong First Quarter 2026 Financial Results Highlighted by $208 Million in Revenue
30/04/2026
Company generates revenue growth for second consecutive quarter driven by retail performance and announces $20 million share repurchase authorization CHICAGO, April 30, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. ( [...]
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
30/04/2026
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone [...]
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
30/04/2026
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑ [...]
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
30/04/2026
ALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer
30/04/2026
Adds accomplished legal and compliance executive with two decades of experience advising healthcare organizations through complex regulatory, governance, and growth initiatives POMPANO BEACH, Fla., April 30, 2026 (GLOBE [...]
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
30/04/2026
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑ [...]
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
30/04/2026
Q1’26 Total Net Revenue of $317 Million, Up 19% YoY Q1’26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 Million Record Quarterly [...]
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
30/04/2026
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
30/04/2026
Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- [...]
EUROAPI_Liquidity Contract
30/04/2026
Press Release Paris 30 avril, 2026 Share buyback program Reduction in the Resources Allocated under the Liquidity Contract with Kepler Cheuvreux By agreement dated 30 May 2022, EUROAPI (ISIN: FR0014008VX5) entrusted [...]
EUROAPI_Contrat de liquidité
30/04/2026
Communiqué de presse Paris, 30 avril 2026 Programme de rachat d’actions Réduction de moyen au contrat de liquidité avec Kepler Cheuvreux Par contrat en date du 30 mai 2022, la société EUROAPI (ISIN: FR0014008VX5) a [...]
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
30/04/2026
OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi® 1 €22.7 and €17.0 million cash position as of December 31, 2025, and March 31, 2026, [...]
OSE Immunotherapeutics publie ses résultats financiers consolidés non audités pour l’exercice 2025 et sa situation de trésorerie du 1er trimestre 2026
30/04/2026
OSE a abordé 2026 avec un plan stratégique clair à 3 ans, axé sur plusieurs catalyseurs à court terme pour lusvertikimab et Tedopi® 1 Trésorerie de 22,7 millions d’euros au 31 décembre 2025 et 17,0 millions d’euros au [...]
Nicox Provides Full Year 2025 Financial Results and Corporate Update
30/04/2026
Press Release Nicox Provides Full Year 2025 Financial Results and Corporate Update Revenue of €16.8 million (€7.9 million in 2024) Net loss significantly reduced to €2.4 million (€22.4 million in 2024) NCX 470 U.S. New [...]
Nicox annonce ses résultats financiers 2025 et fait un point sur son activité
30/04/2026
Communiqué de presse Nicox annonce ses résultats financiers 2025 et fait un point sur son activité Chiffre d’affaires de 16,8 millions d’euros (7,9 millions d’euros en 2024) Perte nette significativement réduite à 2,4 [...]
Valneva Announces the Successful Completion of an €84 million Reserved Offering
30/04/2026
Valneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April 30, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine [...]
Valneva annonce le succès d’une Offre Réservée d’un montant de 84 millions d’euros
30/04/2026
Lyon (France), le 30 avril 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (« Valneva » ou la « Société »), société spécialisée dans les vaccins, annonce le succès d’une offre réservée d’un montant de 84 millions [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum